nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—CHEK2—bone cancer	0.405	0.647	CbGaD
Bosutinib—EGFR—bone cancer	0.162	0.258	CbGaD
Bosutinib—CYP3A4—bone cancer	0.0591	0.0944	CbGaD
Bosutinib—SRMS—knee—bone cancer	0.00613	0.0707	CbGeAlD
Bosutinib—Gefitinib—CHEK2—bone cancer	0.00241	0.472	CrCbGaD
Bosutinib—SRC—periosteum—bone cancer	0.00176	0.0203	CbGeAlD
Bosutinib—RPS6KB1—leg—bone cancer	0.00175	0.0202	CbGeAlD
Bosutinib—RPS6KB1—forelimb—bone cancer	0.00174	0.02	CbGeAlD
Bosutinib—CSF1R—periosteum—bone cancer	0.00158	0.0183	CbGeAlD
Bosutinib—RPS6KB1—hindlimb—bone cancer	0.00156	0.018	CbGeAlD
Bosutinib—RPS6KB1—appendage—bone cancer	0.00134	0.0154	CbGeAlD
Bosutinib—Vandetanib—EGFR—bone cancer	0.00101	0.198	CrCbGaD
Bosutinib—Gefitinib—EGFR—bone cancer	0.000962	0.188	CrCbGaD
Bosutinib—SIK2—connective tissue—bone cancer	0.000808	0.00932	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Epirubicin—bone cancer	0.000787	0.196	CbGdCrCtD
Bosutinib—SRMS—connective tissue—bone cancer	0.000735	0.00848	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—bone cancer	0.000728	0.181	CbGdCrCtD
Bosutinib—SYK—connective tissue—bone cancer	0.000706	0.00815	CbGeAlD
Bosutinib—CDK2—connective tissue—bone cancer	0.0007	0.00807	CbGeAlD
Bosutinib—PLK2—connective tissue—bone cancer	0.000617	0.00711	CbGeAlD
Bosutinib—STK4—connective tissue—bone cancer	0.00059	0.0068	CbGeAlD
Bosutinib—TLK1—tendon—bone cancer	0.000571	0.00659	CbGeAlD
Bosutinib—PRKCQ—tendon—bone cancer	0.000563	0.0065	CbGeAlD
Bosutinib—TYRO3—connective tissue—bone cancer	0.000557	0.00643	CbGeAlD
Bosutinib—ALK—connective tissue—bone cancer	0.000557	0.00643	CbGeAlD
Bosutinib—LYN—connective tissue—bone cancer	0.000554	0.00639	CbGeAlD
Bosutinib—PRKCQ—bone marrow—bone cancer	0.000545	0.00629	CbGeAlD
Bosutinib—BTK—connective tissue—bone cancer	0.000543	0.00627	CbGeAlD
Bosutinib—PRKCQ—spinal cord—bone cancer	0.000543	0.00627	CbGeAlD
Bosutinib—CLK3—tendon—bone cancer	0.000528	0.0061	CbGeAlD
Bosutinib—PKMYT1—bone marrow—bone cancer	0.000524	0.00605	CbGeAlD
Bosutinib—PHKG1—tendon—bone cancer	0.000516	0.00596	CbGeAlD
Bosutinib—ROCK1—connective tissue—bone cancer	0.000514	0.00593	CbGeAlD
Bosutinib—BMX—bone marrow—bone cancer	0.000512	0.0059	CbGeAlD
Bosutinib—CLK3—bone marrow—bone cancer	0.000512	0.0059	CbGeAlD
Bosutinib—EIF2AK1—tendon—bone cancer	0.000511	0.00589	CbGeAlD
Bosutinib—BMPR2—connective tissue—bone cancer	0.000499	0.00576	CbGeAlD
Bosutinib—PHKG1—spinal cord—bone cancer	0.000498	0.00575	CbGeAlD
Bosutinib—VRK2—tendon—bone cancer	0.000495	0.00571	CbGeAlD
Bosutinib—FES—tendon—bone cancer	0.000495	0.00571	CbGeAlD
Bosutinib—EIF2AK1—bone marrow—bone cancer	0.000495	0.00571	CbGeAlD
Bosutinib—EIF2AK1—spinal cord—bone cancer	0.000493	0.00568	CbGeAlD
Bosutinib—SRMS—bone marrow—bone cancer	0.00049	0.00565	CbGeAlD
Bosutinib—TNIK—tendon—bone cancer	0.000486	0.0056	CbGeAlD
Bosutinib—SYK—tendon—bone cancer	0.000486	0.0056	CbGeAlD
Bosutinib—TXK—bone marrow—bone cancer	0.000484	0.00559	CbGeAlD
Bosutinib—CDK2—tendon—bone cancer	0.000481	0.00555	CbGeAlD
Bosutinib—MAP4K4—connective tissue—bone cancer	0.000481	0.00554	CbGeAlD
Bosutinib—FES—bone marrow—bone cancer	0.00048	0.00553	CbGeAlD
Bosutinib—VRK2—bone marrow—bone cancer	0.00048	0.00553	CbGeAlD
Bosutinib—VRK2—spinal cord—bone cancer	0.000478	0.00551	CbGeAlD
Bosutinib—STK26—tendon—bone cancer	0.000477	0.0055	CbGeAlD
Bosutinib—SYK—bone marrow—bone cancer	0.00047	0.00543	CbGeAlD
Bosutinib—SYK—spinal cord—bone cancer	0.000468	0.0054	CbGeAlD
Bosutinib—TNIK—spinal cord—bone cancer	0.000468	0.0054	CbGeAlD
Bosutinib—CDK2—bone marrow—bone cancer	0.000466	0.00538	CbGeAlD
Bosutinib—MAP2K1—connective tissue—bone cancer	0.000464	0.00535	CbGeAlD
Bosutinib—STK26—bone marrow—bone cancer	0.000462	0.00533	CbGeAlD
Bosutinib—CSK—connective tissue—bone cancer	0.000461	0.00532	CbGeAlD
Bosutinib—CHEK2—tendon—bone cancer	0.00046	0.00531	CbGeAlD
Bosutinib—WEE1—tendon—bone cancer	0.000457	0.00527	CbGeAlD
Bosutinib—DMPK—tendon—bone cancer	0.000457	0.00527	CbGeAlD
Bosutinib—CLK1—connective tissue—bone cancer	0.000455	0.00525	CbGeAlD
Bosutinib—BMP2K—connective tissue—bone cancer	0.000447	0.00515	CbGeAlD
Bosutinib—CHEK2—bone marrow—bone cancer	0.000446	0.00514	CbGeAlD
Bosutinib—WEE1—bone marrow—bone cancer	0.000442	0.0051	CbGeAlD
Bosutinib—DMPK—spinal cord—bone cancer	0.00044	0.00508	CbGeAlD
Bosutinib—STK25—tendon—bone cancer	0.000436	0.00503	CbGeAlD
Bosutinib—PTK2B—connective tissue—bone cancer	0.000432	0.00498	CbGeAlD
Bosutinib—PLK2—tendon—bone cancer	0.000424	0.00489	CbGeAlD
Bosutinib—STK25—bone marrow—bone cancer	0.000422	0.00487	CbGeAlD
Bosutinib—SIK3—tendon—bone cancer	0.000421	0.00486	CbGeAlD
Bosutinib—STK25—spinal cord—bone cancer	0.00042	0.00485	CbGeAlD
Bosutinib—SIK1—connective tissue—bone cancer	0.000418	0.00482	CbGeAlD
Bosutinib—ERBB3—connective tissue—bone cancer	0.00041	0.00473	CbGeAlD
Bosutinib—PLK2—spinal cord—bone cancer	0.000409	0.00472	CbGeAlD
Bosutinib—MAP3K2—connective tissue—bone cancer	0.000406	0.00468	CbGeAlD
Bosutinib—CAMK1D—tendon—bone cancer	0.0004	0.00462	CbGeAlD
Bosutinib—PTK2—connective tissue—bone cancer	0.000397	0.00458	CbGeAlD
Bosutinib—STK24—tendon—bone cancer	0.000396	0.00457	CbGeAlD
Bosutinib—Liver injury—Epirubicin—bone cancer	0.00039	0.00481	CcSEcCtD
Bosutinib—Abdominal discomfort—Cisplatin—bone cancer	0.000384	0.00474	CcSEcCtD
Bosutinib—STK24—bone marrow—bone cancer	0.000383	0.00442	CbGeAlD
Bosutinib—FER—tendon—bone cancer	0.000383	0.00442	CbGeAlD
Bosutinib—RPS6KB1—connective tissue—bone cancer	0.000382	0.00441	CbGeAlD
Bosutinib—Pancytopenia—Cisplatin—bone cancer	0.00038	0.0047	CcSEcCtD
Bosutinib—AXL—connective tissue—bone cancer	0.000378	0.00437	CbGeAlD
Bosutinib—MAP4K1—tendon—bone cancer	0.000375	0.00433	CbGeAlD
Bosutinib—BTK—tendon—bone cancer	0.000373	0.00431	CbGeAlD
Bosutinib—Vandetanib—CYP3A4—bone cancer	0.00037	0.0724	CrCbGaD
Bosutinib—FER—spinal cord—bone cancer	0.000369	0.00426	CbGeAlD
Bosutinib—EPHA5—spinal cord—bone cancer	0.000369	0.00426	CbGeAlD
Bosutinib—TYRO3—spinal cord—bone cancer	0.000369	0.00426	CbGeAlD
Bosutinib—MAP4K1—bone marrow—bone cancer	0.000363	0.00419	CbGeAlD
Bosutinib—MAP4K2—tendon—bone cancer	0.000363	0.00419	CbGeAlD
Bosutinib—BTK—bone marrow—bone cancer	0.000362	0.00417	CbGeAlD
Bosutinib—EPHB4—connective tissue—bone cancer	0.000362	0.00417	CbGeAlD
Bosutinib—Liver injury—Doxorubicin—bone cancer	0.00036	0.00445	CcSEcCtD
Bosutinib—BTK—spinal cord—bone cancer	0.00036	0.00415	CbGeAlD
Bosutinib—STK3—tendon—bone cancer	0.000358	0.00413	CbGeAlD
Bosutinib—ERBB4—tendon—bone cancer	0.000358	0.00413	CbGeAlD
Bosutinib—Respiratory failure—Methotrexate—bone cancer	0.000357	0.0044	CcSEcCtD
Bosutinib—FYN—connective tissue—bone cancer	0.000354	0.00409	CbGeAlD
Bosutinib—MAP4K2—bone marrow—bone cancer	0.000351	0.00405	CbGeAlD
Bosutinib—Gefitinib—CYP3A4—bone cancer	0.000351	0.0688	CrCbGaD
Bosutinib—Renal failure—Cisplatin—bone cancer	0.000351	0.00433	CcSEcCtD
Bosutinib—Blood bilirubin increased—Epirubicin—bone cancer	0.000347	0.00428	CcSEcCtD
Bosutinib—ERBB4—spinal cord—bone cancer	0.000345	0.00398	CbGeAlD
Bosutinib—BMPR2—tendon—bone cancer	0.000343	0.00396	CbGeAlD
Bosutinib—STK36—tendon—bone cancer	0.00034	0.00393	CbGeAlD
Bosutinib—Hepatobiliary disease—Cisplatin—bone cancer	0.000338	0.00417	CcSEcCtD
Bosutinib—MERTK—tendon—bone cancer	0.000337	0.00388	CbGeAlD
Bosutinib—MAP4K4—tendon—bone cancer	0.00033	0.00381	CbGeAlD
Bosutinib—EPHB3—spinal cord—bone cancer	0.000328	0.00379	CbGeAlD
Bosutinib—BCR—tendon—bone cancer	0.000328	0.00378	CbGeAlD
Bosutinib—MERTK—bone marrow—bone cancer	0.000326	0.00376	CbGeAlD
Bosutinib—MAP3K12—tendon—bone cancer	0.000326	0.00376	CbGeAlD
Bosutinib—Hyperkalaemia—Epirubicin—bone cancer	0.000322	0.00398	CcSEcCtD
Bosutinib—Blood bilirubin increased—Doxorubicin—bone cancer	0.000321	0.00396	CcSEcCtD
Bosutinib—MAP4K4—bone marrow—bone cancer	0.00032	0.00369	CbGeAlD
Bosutinib—YES1—connective tissue—bone cancer	0.00032	0.00369	CbGeAlD
Bosutinib—STK35—tendon—bone cancer	0.000319	0.00368	CbGeAlD
Bosutinib—MAP4K4—spinal cord—bone cancer	0.000319	0.00368	CbGeAlD
Bosutinib—BCR—bone marrow—bone cancer	0.000318	0.00367	CbGeAlD
Bosutinib—NUAK2—bone marrow—bone cancer	0.000318	0.00367	CbGeAlD
Bosutinib—CSK—tendon—bone cancer	0.000317	0.00366	CbGeAlD
Bosutinib—Urinary tract disorder—Cisplatin—bone cancer	0.000317	0.00391	CcSEcCtD
Bosutinib—BCR—spinal cord—bone cancer	0.000316	0.00365	CbGeAlD
Bosutinib—TAOK3—connective tissue—bone cancer	0.000316	0.00364	CbGeAlD
Bosutinib—Connective tissue disorder—Cisplatin—bone cancer	0.000315	0.00389	CcSEcCtD
Bosutinib—CSNK1A1—tendon—bone cancer	0.000315	0.00363	CbGeAlD
Bosutinib—Urethral disorder—Cisplatin—bone cancer	0.000314	0.00388	CcSEcCtD
Bosutinib—MAP3K12—spinal cord—bone cancer	0.000314	0.00362	CbGeAlD
Bosutinib—HCK—tendon—bone cancer	0.000313	0.00361	CbGeAlD
Bosutinib—CLK1—tendon—bone cancer	0.000313	0.00361	CbGeAlD
Bosutinib—Fluid retention—Epirubicin—bone cancer	0.000311	0.00384	CcSEcCtD
Bosutinib—ABL2—tendon—bone cancer	0.000311	0.00359	CbGeAlD
Bosutinib—MAP2K1—bone marrow—bone cancer	0.000309	0.00357	CbGeAlD
Bosutinib—MAP2K1—spinal cord—bone cancer	0.000308	0.00355	CbGeAlD
Bosutinib—SRC—connective tissue—bone cancer	0.000307	0.00355	CbGeAlD
Bosutinib—CAMK2G—tendon—bone cancer	0.000307	0.00354	CbGeAlD
Bosutinib—BMP2K—tendon—bone cancer	0.000307	0.00354	CbGeAlD
Bosutinib—CSK—bone marrow—bone cancer	0.000307	0.00354	CbGeAlD
Bosutinib—CSK—spinal cord—bone cancer	0.000306	0.00353	CbGeAlD
Bosutinib—CSNK1A1—bone marrow—bone cancer	0.000305	0.00352	CbGeAlD
Bosutinib—LRRK2—tendon—bone cancer	0.000304	0.00351	CbGeAlD
Bosutinib—CSNK1A1—spinal cord—bone cancer	0.000304	0.0035	CbGeAlD
Bosutinib—HCK—bone marrow—bone cancer	0.000303	0.0035	CbGeAlD
Bosutinib—CLK1—bone marrow—bone cancer	0.000303	0.0035	CbGeAlD
Bosutinib—HCK—spinal cord—bone cancer	0.000302	0.00348	CbGeAlD
Bosutinib—CLK1—spinal cord—bone cancer	0.000302	0.00348	CbGeAlD
Bosutinib—Tinnitus—Cisplatin—bone cancer	0.000299	0.00369	CcSEcCtD
Bosutinib—Hyperkalaemia—Doxorubicin—bone cancer	0.000298	0.00368	CcSEcCtD
Bosutinib—Rash maculo-papular—Epirubicin—bone cancer	0.000298	0.00368	CcSEcCtD
Bosutinib—Cardiac disorder—Cisplatin—bone cancer	0.000298	0.00367	CcSEcCtD
Bosutinib—BMP2K—bone marrow—bone cancer	0.000297	0.00343	CbGeAlD
Bosutinib—CAMK2G—bone marrow—bone cancer	0.000297	0.00343	CbGeAlD
Bosutinib—PTK2B—tendon—bone cancer	0.000297	0.00342	CbGeAlD
Bosutinib—BMP2K—spinal cord—bone cancer	0.000296	0.00342	CbGeAlD
Bosutinib—CAMK2G—spinal cord—bone cancer	0.000296	0.00342	CbGeAlD
Bosutinib—LRRK2—bone marrow—bone cancer	0.000295	0.0034	CbGeAlD
Bosutinib—LRRK2—spinal cord—bone cancer	0.000294	0.00339	CbGeAlD
Bosutinib—CSNK1E—tendon—bone cancer	0.000292	0.00337	CbGeAlD
Bosutinib—Immune system disorder—Cisplatin—bone cancer	0.00029	0.00357	CcSEcCtD
Bosutinib—Mediastinal disorder—Cisplatin—bone cancer	0.000289	0.00357	CcSEcCtD
Bosutinib—Fluid retention—Doxorubicin—bone cancer	0.000288	0.00356	CcSEcCtD
Bosutinib—PTK2B—bone marrow—bone cancer	0.000287	0.00331	CbGeAlD
Bosutinib—SIK1—tendon—bone cancer	0.000287	0.00331	CbGeAlD
Bosutinib—IRAK4—tendon—bone cancer	0.000287	0.00331	CbGeAlD
Bosutinib—EPHA4—tendon—bone cancer	0.000284	0.00328	CbGeAlD
Bosutinib—CSNK1E—spinal cord—bone cancer	0.000281	0.00325	CbGeAlD
Bosutinib—MAP2K2—tendon—bone cancer	0.000281	0.00324	CbGeAlD
Bosutinib—ULK3—tendon—bone cancer	0.000281	0.00324	CbGeAlD
Bosutinib—Malnutrition—Cisplatin—bone cancer	0.000279	0.00345	CcSEcCtD
Bosutinib—SIK1—bone marrow—bone cancer	0.000278	0.00321	CbGeAlD
Bosutinib—IRAK4—bone marrow—bone cancer	0.000278	0.00321	CbGeAlD
Bosutinib—SIK1—spinal cord—bone cancer	0.000277	0.0032	CbGeAlD
Bosutinib—IRAK4—spinal cord—bone cancer	0.000277	0.0032	CbGeAlD
Bosutinib—MAP3K7—tendon—bone cancer	0.000276	0.00319	CbGeAlD
Bosutinib—CSF1R—connective tissue—bone cancer	0.000276	0.00318	CbGeAlD
Bosutinib—Rash maculo-papular—Doxorubicin—bone cancer	0.000276	0.0034	CcSEcCtD
Bosutinib—Renal failure acute—Methotrexate—bone cancer	0.000275	0.0034	CcSEcCtD
Bosutinib—TBK1—tendon—bone cancer	0.000273	0.00315	CbGeAlD
Bosutinib—PTK2—tendon—bone cancer	0.000273	0.00315	CbGeAlD
Bosutinib—Hepatic function abnormal—Epirubicin—bone cancer	0.000272	0.00336	CcSEcCtD
Bosutinib—MAP2K2—bone marrow—bone cancer	0.000272	0.00314	CbGeAlD
Bosutinib—ULK3—bone marrow—bone cancer	0.000272	0.00314	CbGeAlD
Bosutinib—ERBB3—spinal cord—bone cancer	0.000272	0.00313	CbGeAlD
Bosutinib—ULK3—spinal cord—bone cancer	0.000271	0.00313	CbGeAlD
Bosutinib—MAP2K2—spinal cord—bone cancer	0.000271	0.00313	CbGeAlD
Bosutinib—MAP3K2—bone marrow—bone cancer	0.00027	0.00312	CbGeAlD
Bosutinib—CSK—Doxorubicin—Epirubicin—bone cancer	0.000269	0.067	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Epirubicin—bone cancer	0.000269	0.067	CbGdCrCtD
Bosutinib—IRAK1—tendon—bone cancer	0.000268	0.00309	CbGeAlD
Bosutinib—MAP3K7—bone marrow—bone cancer	0.000268	0.00309	CbGeAlD
Bosutinib—MAP3K7—spinal cord—bone cancer	0.000266	0.00307	CbGeAlD
Bosutinib—TBK1—bone marrow—bone cancer	0.000265	0.00305	CbGeAlD
Bosutinib—TBK1—spinal cord—bone cancer	0.000263	0.00304	CbGeAlD
Bosutinib—PTK2—spinal cord—bone cancer	0.000263	0.00304	CbGeAlD
Bosutinib—RPS6KB1—tendon—bone cancer	0.000263	0.00303	CbGeAlD
Bosutinib—FGR—tendon—bone cancer	0.000261	0.00301	CbGeAlD
Bosutinib—AXL—tendon—bone cancer	0.00026	0.003	CbGeAlD
Bosutinib—IRAK1—bone marrow—bone cancer	0.000259	0.00299	CbGeAlD
Bosutinib—Ill-defined disorder—Cisplatin—bone cancer	0.000259	0.0032	CcSEcCtD
Bosutinib—Anaemia—Cisplatin—bone cancer	0.000258	0.00318	CcSEcCtD
Bosutinib—Renal failure acute—Epirubicin—bone cancer	0.000258	0.00318	CcSEcCtD
Bosutinib—RPS6KB1—bone marrow—bone cancer	0.000255	0.00294	CbGeAlD
Bosutinib—RPS6KB1—spinal cord—bone cancer	0.000253	0.00292	CbGeAlD
Bosutinib—FGR—bone marrow—bone cancer	0.000253	0.00292	CbGeAlD
Bosutinib—LCK—bone marrow—bone cancer	0.000253	0.00292	CbGeAlD
Bosutinib—Hepatic function abnormal—Doxorubicin—bone cancer	0.000252	0.00311	CcSEcCtD
Bosutinib—Malaise—Cisplatin—bone cancer	0.000252	0.00311	CcSEcCtD
Bosutinib—AXL—spinal cord—bone cancer	0.000251	0.00289	CbGeAlD
Bosutinib—SLK—tendon—bone cancer	0.00025	0.00289	CbGeAlD
Bosutinib—Renal impairment—Epirubicin—bone cancer	0.00025	0.00309	CcSEcCtD
Bosutinib—Leukopenia—Cisplatin—bone cancer	0.00025	0.00308	CcSEcCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—bone cancer	0.000249	0.062	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—bone cancer	0.000249	0.062	CbGdCrCtD
Bosutinib—EPHB4—tendon—bone cancer	0.000249	0.00287	CbGeAlD
Bosutinib—PDGFRB—connective tissue—bone cancer	0.000245	0.00282	CbGeAlD
Bosutinib—EPHA2—tendon—bone cancer	0.000244	0.00281	CbGeAlD
Bosutinib—FYN—tendon—bone cancer	0.000243	0.00281	CbGeAlD
Bosutinib—SLK—bone marrow—bone cancer	0.000243	0.0028	CbGeAlD
Bosutinib—SLK—spinal cord—bone cancer	0.000241	0.00279	CbGeAlD
Bosutinib—EPHB4—bone marrow—bone cancer	0.000241	0.00278	CbGeAlD
Bosutinib—EPHB4—spinal cord—bone cancer	0.00024	0.00277	CbGeAlD
Bosutinib—Renal failure acute—Doxorubicin—bone cancer	0.000238	0.00294	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000238	0.00294	CcSEcCtD
Bosutinib—MAP4K5—tendon—bone cancer	0.000238	0.00274	CbGeAlD
Bosutinib—MAP3K3—tendon—bone cancer	0.000238	0.00274	CbGeAlD
Bosutinib—Myalgia—Cisplatin—bone cancer	0.000238	0.00293	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000236	0.00291	CcSEcCtD
Bosutinib—FYN—bone marrow—bone cancer	0.000236	0.00272	CbGeAlD
Bosutinib—FYN—spinal cord—bone cancer	0.000235	0.00271	CbGeAlD
Bosutinib—Discomfort—Cisplatin—bone cancer	0.000235	0.0029	CcSEcCtD
Bosutinib—Renal impairment—Doxorubicin—bone cancer	0.000231	0.00286	CcSEcCtD
Bosutinib—MAP4K5—bone marrow—bone cancer	0.00023	0.00266	CbGeAlD
Bosutinib—MAP3K3—bone marrow—bone cancer	0.00023	0.00266	CbGeAlD
Bosutinib—Face oedema—Epirubicin—bone cancer	0.00023	0.00284	CcSEcCtD
Bosutinib—MAP3K3—spinal cord—bone cancer	0.000229	0.00265	CbGeAlD
Bosutinib—MAP4K5—spinal cord—bone cancer	0.000229	0.00265	CbGeAlD
Bosutinib—Anaphylactic shock—Cisplatin—bone cancer	0.000228	0.00281	CcSEcCtD
Bosutinib—Oedema—Cisplatin—bone cancer	0.000228	0.00281	CcSEcCtD
Bosutinib—Infection—Cisplatin—bone cancer	0.000226	0.00279	CcSEcCtD
Bosutinib—Nervous system disorder—Cisplatin—bone cancer	0.000223	0.00276	CcSEcCtD
Bosutinib—Thrombocytopenia—Cisplatin—bone cancer	0.000223	0.00275	CcSEcCtD
Bosutinib—Blood creatinine increased—Epirubicin—bone cancer	0.000223	0.00275	CcSEcCtD
Bosutinib—Dehydration—Epirubicin—bone cancer	0.000221	0.00273	CcSEcCtD
Bosutinib—Skin disorder—Cisplatin—bone cancer	0.000221	0.00273	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.00022	0.00272	CcSEcCtD
Bosutinib—YES1—tendon—bone cancer	0.00022	0.00253	CbGeAlD
Bosutinib—ABL1—connective tissue—bone cancer	0.000218	0.00252	CbGeAlD
Bosutinib—STK10—tendon—bone cancer	0.000218	0.00251	CbGeAlD
Bosutinib—Abdominal pain upper—Epirubicin—bone cancer	0.000217	0.00268	CcSEcCtD
Bosutinib—TAOK3—tendon—bone cancer	0.000217	0.0025	CbGeAlD
Bosutinib—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000214	0.00265	CcSEcCtD
Bosutinib—YES1—bone marrow—bone cancer	0.000213	0.00245	CbGeAlD
Bosutinib—Nasopharyngitis—Epirubicin—bone cancer	0.000213	0.00263	CcSEcCtD
Bosutinib—Face oedema—Doxorubicin—bone cancer	0.000213	0.00262	CcSEcCtD
Bosutinib—YES1—spinal cord—bone cancer	0.000212	0.00244	CbGeAlD
Bosutinib—STK10—bone marrow—bone cancer	0.000211	0.00243	CbGeAlD
Bosutinib—Abdominal discomfort—Methotrexate—bone cancer	0.000211	0.0026	CcSEcCtD
Bosutinib—Gastritis—Epirubicin—bone cancer	0.000211	0.0026	CcSEcCtD
Bosutinib—TAOK3—bone marrow—bone cancer	0.00021	0.00242	CbGeAlD
Bosutinib—Alanine aminotransferase increased—Epirubicin—bone cancer	0.00021	0.00259	CcSEcCtD
Bosutinib—TAOK3—spinal cord—bone cancer	0.000209	0.00241	CbGeAlD
Bosutinib—Pancytopenia—Methotrexate—bone cancer	0.000209	0.00258	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000208	0.00256	CcSEcCtD
Bosutinib—Blood creatinine increased—Doxorubicin—bone cancer	0.000206	0.00255	CcSEcCtD
Bosutinib—Influenza—Epirubicin—bone cancer	0.000206	0.00254	CcSEcCtD
Bosutinib—Neutropenia—Methotrexate—bone cancer	0.000206	0.00254	CcSEcCtD
Bosutinib—Dehydration—Doxorubicin—bone cancer	0.000205	0.00253	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Methotrexate—bone cancer	0.000204	0.00252	CcSEcCtD
Bosutinib—SRC—spinal cord—bone cancer	0.000204	0.00235	CbGeAlD
Bosutinib—Dyspnoea—Cisplatin—bone cancer	0.000203	0.00251	CcSEcCtD
Bosutinib—Abdominal pain upper—Doxorubicin—bone cancer	0.000201	0.00248	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000198	0.00245	CcSEcCtD
Bosutinib—Decreased appetite—Cisplatin—bone cancer	0.000198	0.00244	CcSEcCtD
Bosutinib—Bronchitis—Epirubicin—bone cancer	0.000198	0.00244	CcSEcCtD
Bosutinib—Pneumonia—Methotrexate—bone cancer	0.000197	0.00243	CcSEcCtD
Bosutinib—Nasopharyngitis—Doxorubicin—bone cancer	0.000197	0.00243	CcSEcCtD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—bone cancer	0.000197	0.049	CbGdCrCtD
Bosutinib—Gastrointestinal disorder—Cisplatin—bone cancer	0.000197	0.00243	CcSEcCtD
Bosutinib—Infestation—Methotrexate—bone cancer	0.000196	0.00242	CcSEcCtD
Bosutinib—Infestation NOS—Methotrexate—bone cancer	0.000196	0.00242	CcSEcCtD
Bosutinib—Pancytopenia—Epirubicin—bone cancer	0.000195	0.00241	CcSEcCtD
Bosutinib—Gastritis—Doxorubicin—bone cancer	0.000195	0.00241	CcSEcCtD
Bosutinib—Pain—Cisplatin—bone cancer	0.000195	0.0024	CcSEcCtD
Bosutinib—MAP2K5—tendon—bone cancer	0.000194	0.00224	CbGeAlD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000194	0.0024	CcSEcCtD
Bosutinib—Renal failure—Methotrexate—bone cancer	0.000193	0.00238	CcSEcCtD
Bosutinib—Neutropenia—Epirubicin—bone cancer	0.000192	0.00237	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Epirubicin—bone cancer	0.000191	0.00236	CcSEcCtD
Bosutinib—Influenza—Doxorubicin—bone cancer	0.00019	0.00235	CcSEcCtD
Bosutinib—CSF1R—tendon—bone cancer	0.00019	0.00219	CbGeAlD
Bosutinib—ABL1—Idarubicin—Epirubicin—bone cancer	0.000188	0.0468	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—bone cancer	0.000188	0.0468	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—bone cancer	0.000188	0.0468	CbGdCrCtD
Bosutinib—Feeling abnormal—Cisplatin—bone cancer	0.000188	0.00232	CcSEcCtD
Bosutinib—MAP2K5—spinal cord—bone cancer	0.000188	0.00216	CbGeAlD
Bosutinib—Hepatobiliary disease—Methotrexate—bone cancer	0.000185	0.00229	CcSEcCtD
Bosutinib—Pneumonia—Epirubicin—bone cancer	0.000184	0.00228	CcSEcCtD
Bosutinib—CSF1R—bone marrow—bone cancer	0.000184	0.00212	CbGeAlD
Bosutinib—Infestation NOS—Epirubicin—bone cancer	0.000183	0.00226	CcSEcCtD
Bosutinib—Infestation—Epirubicin—bone cancer	0.000183	0.00226	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—bone cancer	0.000183	0.00226	CcSEcCtD
Bosutinib—CSF1R—spinal cord—bone cancer	0.000183	0.00211	CbGeAlD
Bosutinib—Agranulocytosis—Methotrexate—bone cancer	0.000183	0.00226	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—bone cancer	0.000182	0.0454	CbGdCrCtD
Bosutinib—Pancytopenia—Doxorubicin—bone cancer	0.000181	0.00223	CcSEcCtD
Bosutinib—Renal failure—Epirubicin—bone cancer	0.00018	0.00223	CcSEcCtD
Bosutinib—Body temperature increased—Cisplatin—bone cancer	0.00018	0.00222	CcSEcCtD
Bosutinib—Neutropenia—Doxorubicin—bone cancer	0.000178	0.0022	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000177	0.00218	CcSEcCtD
Bosutinib—Hepatitis—Methotrexate—bone cancer	0.000176	0.00217	CcSEcCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—bone cancer	0.000174	0.0433	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—bone cancer	0.000174	0.0433	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—bone cancer	0.000174	0.0433	CbGdCrCtD
Bosutinib—Urinary tract disorder—Methotrexate—bone cancer	0.000174	0.00214	CcSEcCtD
Bosutinib—Hepatobiliary disease—Epirubicin—bone cancer	0.000173	0.00214	CcSEcCtD
Bosutinib—Urethral disorder—Methotrexate—bone cancer	0.000172	0.00213	CcSEcCtD
Bosutinib—Agranulocytosis—Epirubicin—bone cancer	0.000171	0.00211	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—bone cancer	0.000171	0.00211	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—bone cancer	0.00017	0.00209	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—bone cancer	0.00017	0.00209	CcSEcCtD
Bosutinib—PDGFRB—tendon—bone cancer	0.000168	0.00194	CbGeAlD
Bosutinib—Renal failure—Doxorubicin—bone cancer	0.000167	0.00206	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—bone cancer	0.000166	0.00205	CcSEcCtD
Bosutinib—Hepatitis—Epirubicin—bone cancer	0.000165	0.00203	CcSEcCtD
Bosutinib—Tinnitus—Methotrexate—bone cancer	0.000164	0.00202	CcSEcCtD
Bosutinib—Asthenia—Cisplatin—bone cancer	0.000163	0.00202	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—bone cancer	0.000163	0.00202	CcSEcCtD
Bosutinib—PDGFRB—bone marrow—bone cancer	0.000163	0.00188	CbGeAlD
Bosutinib—Urinary tract disorder—Epirubicin—bone cancer	0.000163	0.00201	CcSEcCtD
Bosutinib—PDGFRB—spinal cord—bone cancer	0.000162	0.00187	CbGeAlD
Bosutinib—Oedema peripheral—Epirubicin—bone cancer	0.000162	0.002	CcSEcCtD
Bosutinib—Connective tissue disorder—Epirubicin—bone cancer	0.000162	0.002	CcSEcCtD
Bosutinib—Urethral disorder—Epirubicin—bone cancer	0.000161	0.00199	CcSEcCtD
Bosutinib—Hepatobiliary disease—Doxorubicin—bone cancer	0.00016	0.00198	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—bone cancer	0.000159	0.00196	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—bone cancer	0.000159	0.00196	CcSEcCtD
Bosutinib—Agranulocytosis—Doxorubicin—bone cancer	0.000158	0.00195	CcSEcCtD
Bosutinib—Diarrhoea—Cisplatin—bone cancer	0.000156	0.00192	CcSEcCtD
Bosutinib—Erythema multiforme—Epirubicin—bone cancer	0.000156	0.00192	CcSEcCtD
Bosutinib—Tinnitus—Epirubicin—bone cancer	0.000153	0.00189	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—bone cancer	0.000153	0.00189	CcSEcCtD
Bosutinib—Cardiac disorder—Epirubicin—bone cancer	0.000153	0.00189	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—bone cancer	0.000152	0.00188	CcSEcCtD
Bosutinib—Urinary tract disorder—Doxorubicin—bone cancer	0.00015	0.00186	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—bone cancer	0.00015	0.00185	CcSEcCtD
Bosutinib—ABL1—tendon—bone cancer	0.00015	0.00173	CbGeAlD
Bosutinib—Dysgeusia—Methotrexate—bone cancer	0.00015	0.00185	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—bone cancer	0.00015	0.00185	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—bone cancer	0.000149	0.00184	CcSEcCtD
Bosutinib—Immune system disorder—Epirubicin—bone cancer	0.000149	0.00184	CcSEcCtD
Bosutinib—Mediastinal disorder—Epirubicin—bone cancer	0.000148	0.00183	CcSEcCtD
Bosutinib—Back pain—Methotrexate—bone cancer	0.000148	0.00183	CcSEcCtD
Bosutinib—ABL1—bone marrow—bone cancer	0.000145	0.00168	CbGeAlD
Bosutinib—Vomiting—Cisplatin—bone cancer	0.000145	0.00179	CcSEcCtD
Bosutinib—ABL1—spinal cord—bone cancer	0.000145	0.00167	CbGeAlD
Bosutinib—Erythema multiforme—Doxorubicin—bone cancer	0.000144	0.00178	CcSEcCtD
Bosutinib—Rash—Cisplatin—bone cancer	0.000144	0.00177	CcSEcCtD
Bosutinib—Dermatitis—Cisplatin—bone cancer	0.000143	0.00177	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—bone cancer	0.000143	0.00177	CcSEcCtD
Bosutinib—Ill-defined disorder—Methotrexate—bone cancer	0.000142	0.00175	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—bone cancer	0.000142	0.00175	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—bone cancer	0.000142	0.00175	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—bone cancer	0.000141	0.00175	CcSEcCtD
Bosutinib—Dysgeusia—Epirubicin—bone cancer	0.00014	0.00173	CcSEcCtD
Bosutinib—Back pain—Epirubicin—bone cancer	0.000139	0.00171	CcSEcCtD
Bosutinib—Malaise—Methotrexate—bone cancer	0.000138	0.0017	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—bone cancer	0.000138	0.0017	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—bone cancer	0.000137	0.00169	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—bone cancer	0.000137	0.00169	CcSEcCtD
Bosutinib—Nausea—Cisplatin—bone cancer	0.000135	0.00167	CcSEcCtD
Bosutinib—Cough—Methotrexate—bone cancer	0.000134	0.00165	CcSEcCtD
Bosutinib—Ill-defined disorder—Epirubicin—bone cancer	0.000133	0.00164	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—bone cancer	0.000133	0.00164	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—bone cancer	0.000132	0.00164	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—bone cancer	0.00013	0.00161	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—bone cancer	0.00013	0.00161	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—bone cancer	0.00013	0.00161	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—bone cancer	0.00013	0.0016	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000129	0.0016	CcSEcCtD
Bosutinib—Malaise—Epirubicin—bone cancer	0.000129	0.0016	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—bone cancer	0.000129	0.00159	CcSEcCtD
Bosutinib—Leukopenia—Epirubicin—bone cancer	0.000128	0.00158	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—bone cancer	0.000128	0.00158	CcSEcCtD
Bosutinib—Cough—Epirubicin—bone cancer	0.000125	0.00154	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—bone cancer	0.000125	0.00154	CcSEcCtD
Bosutinib—Infection—Methotrexate—bone cancer	0.000124	0.00153	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—bone cancer	0.000123	0.00152	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—bone cancer	0.000123	0.00151	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—bone cancer	0.000123	0.00151	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—bone cancer	0.000122	0.00151	CcSEcCtD
Bosutinib—Chest pain—Epirubicin—bone cancer	0.000122	0.00151	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—bone cancer	0.000122	0.00151	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—bone cancer	0.000122	0.00151	CcSEcCtD
Bosutinib—Skin disorder—Methotrexate—bone cancer	0.000121	0.0015	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000121	0.0015	CcSEcCtD
Bosutinib—Discomfort—Epirubicin—bone cancer	0.000121	0.00149	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—bone cancer	0.00012	0.00148	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—bone cancer	0.000119	0.00147	CcSEcCtD
Bosutinib—Anaphylactic shock—Epirubicin—bone cancer	0.000117	0.00144	CcSEcCtD
Bosutinib—Oedema—Epirubicin—bone cancer	0.000117	0.00144	CcSEcCtD
Bosutinib—Infection—Epirubicin—bone cancer	0.000116	0.00143	CcSEcCtD
Bosutinib—Cough—Doxorubicin—bone cancer	0.000116	0.00143	CcSEcCtD
Bosutinib—Nervous system disorder—Epirubicin—bone cancer	0.000115	0.00142	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—bone cancer	0.000115	0.00141	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000114	0.00141	CcSEcCtD
Bosutinib—Skin disorder—Epirubicin—bone cancer	0.000114	0.0014	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—bone cancer	0.000113	0.00139	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—bone cancer	0.000113	0.00139	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—bone cancer	0.000113	0.00139	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000112	0.00138	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—bone cancer	0.000112	0.00138	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—bone cancer	0.000111	0.00138	CcSEcCtD
Bosutinib—Decreased appetite—Methotrexate—bone cancer	0.000109	0.00134	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—bone cancer	0.000108	0.00134	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—bone cancer	0.000108	0.00134	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—bone cancer	0.000108	0.00133	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—bone cancer	0.000108	0.00133	CcSEcCtD
Bosutinib—Infection—Doxorubicin—bone cancer	0.000108	0.00133	CcSEcCtD
Bosutinib—Pain—Methotrexate—bone cancer	0.000107	0.00132	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000107	0.00132	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—bone cancer	0.000106	0.00131	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—bone cancer	0.000106	0.00131	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—bone cancer	0.000105	0.0013	CcSEcCtD
Bosutinib—Dyspnoea—Epirubicin—bone cancer	0.000104	0.00129	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—bone cancer	0.000103	0.00127	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—bone cancer	0.000102	0.00126	CcSEcCtD
Bosutinib—Decreased appetite—Epirubicin—bone cancer	0.000102	0.00126	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—bone cancer	0.000101	0.00125	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—bone cancer	0.000101	0.00124	CcSEcCtD
Bosutinib—Pain—Epirubicin—bone cancer	0.0001	0.00123	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—bone cancer	9.93e-05	0.00123	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—bone cancer	9.88e-05	0.00122	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—bone cancer	9.88e-05	0.00122	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—bone cancer	9.86e-05	0.00122	CcSEcCtD
Bosutinib—Dyspnoea—Doxorubicin—bone cancer	9.65e-05	0.00119	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—bone cancer	9.64e-05	0.00119	CcSEcCtD
Bosutinib—Gastrointestinal pain—Epirubicin—bone cancer	9.56e-05	0.00118	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—bone cancer	9.41e-05	0.00116	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—bone cancer	9.34e-05	0.00115	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—bone cancer	9.33e-05	0.00115	CcSEcCtD
Bosutinib—Urticaria—Epirubicin—bone cancer	9.29e-05	0.00115	CcSEcCtD
Bosutinib—Pain—Doxorubicin—bone cancer	9.25e-05	0.00114	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—bone cancer	9.25e-05	0.00114	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—bone cancer	9.25e-05	0.00114	CcSEcCtD
Bosutinib—Asthenia—Methotrexate—bone cancer	8.97e-05	0.00111	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—bone cancer	8.92e-05	0.0011	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—bone cancer	8.85e-05	0.00109	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—bone cancer	8.84e-05	0.00109	CcSEcCtD
Bosutinib—Urticaria—Doxorubicin—bone cancer	8.6e-05	0.00106	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—bone cancer	8.56e-05	0.00106	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—bone cancer	8.56e-05	0.00106	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—bone cancer	8.55e-05	0.00106	CcSEcCtD
Bosutinib—Asthenia—Epirubicin—bone cancer	8.39e-05	0.00104	CcSEcCtD
Bosutinib—Pruritus—Epirubicin—bone cancer	8.27e-05	0.00102	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—bone cancer	8.26e-05	0.00102	CcSEcCtD
Bosutinib—Diarrhoea—Epirubicin—bone cancer	8e-05	0.000988	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—bone cancer	7.95e-05	0.000981	CcSEcCtD
Bosutinib—Rash—Methotrexate—bone cancer	7.88e-05	0.000973	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—bone cancer	7.87e-05	0.000972	CcSEcCtD
Bosutinib—Headache—Methotrexate—bone cancer	7.83e-05	0.000967	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—bone cancer	7.76e-05	0.000959	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—bone cancer	7.73e-05	0.000955	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—bone cancer	7.66e-05	0.000945	CcSEcCtD
Bosutinib—Vomiting—Epirubicin—bone cancer	7.44e-05	0.000918	CcSEcCtD
Bosutinib—Nausea—Methotrexate—bone cancer	7.42e-05	0.000916	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—bone cancer	7.4e-05	0.000914	CcSEcCtD
Bosutinib—Rash—Epirubicin—bone cancer	7.37e-05	0.00091	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—bone cancer	7.37e-05	0.00091	CcSEcCtD
Bosutinib—Headache—Epirubicin—bone cancer	7.33e-05	0.000905	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—bone cancer	7.16e-05	0.000883	CcSEcCtD
Bosutinib—Nausea—Epirubicin—bone cancer	6.95e-05	0.000858	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—bone cancer	6.88e-05	0.000849	CcSEcCtD
Bosutinib—Rash—Doxorubicin—bone cancer	6.82e-05	0.000842	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—bone cancer	6.82e-05	0.000842	CcSEcCtD
Bosutinib—Headache—Doxorubicin—bone cancer	6.78e-05	0.000837	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—bone cancer	6.43e-05	0.000794	CcSEcCtD
Bosutinib—ABCB1—bone marrow—bone cancer	4.52e-05	0.000521	CbGeAlD
Bosutinib—ABCB1—spinal cord—bone cancer	4.5e-05	0.000519	CbGeAlD
Bosutinib—PTK2—Immune System—JUN—bone cancer	3.66e-06	1.85e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—BRAF—bone cancer	3.65e-06	1.85e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFBR2—bone cancer	3.65e-06	1.85e-05	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—EGFR—bone cancer	3.64e-06	1.84e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—EGFR—bone cancer	3.62e-06	1.83e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—EGFR—bone cancer	3.62e-06	1.83e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—JUN—bone cancer	3.61e-06	1.83e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—EGFR—bone cancer	3.6e-06	1.82e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IGF1R—bone cancer	3.58e-06	1.81e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—EGFR—bone cancer	3.58e-06	1.81e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—KIT—bone cancer	3.58e-06	1.81e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—BRAF—bone cancer	3.58e-06	1.81e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL3—bone cancer	3.57e-06	1.81e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—EGFR—bone cancer	3.57e-06	1.81e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—EGFR—bone cancer	3.56e-06	1.8e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KIT—bone cancer	3.56e-06	1.8e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—EGFR—bone cancer	3.53e-06	1.79e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—EGFR—bone cancer	3.52e-06	1.78e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IGF1R—bone cancer	3.51e-06	1.78e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—JUN—bone cancer	3.49e-06	1.77e-05	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—EGFR—bone cancer	3.49e-06	1.77e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—GNA11—bone cancer	3.49e-06	1.77e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—BRAF—bone cancer	3.49e-06	1.77e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MDM2—bone cancer	3.47e-06	1.76e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—EGFR—bone cancer	3.46e-06	1.75e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KIT—bone cancer	3.46e-06	1.75e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IGF1R—bone cancer	3.45e-06	1.75e-05	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—EGFR—bone cancer	3.44e-06	1.74e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IGF1R—bone cancer	3.44e-06	1.74e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—JUN—bone cancer	3.43e-06	1.73e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MDM2—bone cancer	3.42e-06	1.73e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—TP53—bone cancer	3.42e-06	1.73e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KIT—bone cancer	3.41e-06	1.73e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—EGFR—bone cancer	3.4e-06	1.72e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—EGFR—bone cancer	3.4e-06	1.72e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—MMP9—bone cancer	3.4e-06	1.72e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—TP53—bone cancer	3.39e-06	1.72e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—EGFR—bone cancer	3.39e-06	1.72e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—TP53—bone cancer	3.38e-06	1.71e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—BRAF—bone cancer	3.36e-06	1.7e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—JUN—bone cancer	3.36e-06	1.7e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KIT—bone cancer	3.35e-06	1.69e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—BRAF—bone cancer	3.34e-06	1.69e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—TP53—bone cancer	3.34e-06	1.69e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MDM2—bone cancer	3.3e-06	1.67e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—EGFR—bone cancer	3.28e-06	1.66e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—BRAF—bone cancer	3.25e-06	1.65e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ATF1—bone cancer	3.24e-06	1.64e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—MDM2—bone cancer	3.24e-06	1.64e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KIT—bone cancer	3.24e-06	1.64e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—EGFR—bone cancer	3.24e-06	1.64e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—JUN—bone cancer	3.23e-06	1.63e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—KIT—bone cancer	3.23e-06	1.63e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—BRAF—bone cancer	3.21e-06	1.62e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MDM2—bone cancer	3.18e-06	1.61e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MDM2—bone cancer	3.18e-06	1.61e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.17e-06	1.61e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFBR2—bone cancer	3.17e-06	1.61e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—MDM2—bone cancer	3.17e-06	1.6e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL3—bone cancer	3.16e-06	1.6e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—MDM2—bone cancer	3.1e-06	1.57e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—KIT—bone cancer	3.09e-06	1.56e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—MDM2—bone cancer	3.09e-06	1.56e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MDM2—bone cancer	3.06e-06	1.55e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFBR2—bone cancer	3.06e-06	1.55e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—MDM2—bone cancer	3.05e-06	1.54e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KIT—bone cancer	3.05e-06	1.54e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—BRAF—bone cancer	3.04e-06	1.54e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—MDM2—bone cancer	3.04e-06	1.54e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—JUN—bone cancer	3.02e-06	1.53e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—MDM2—bone cancer	3e-06	1.52e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—EGFR—bone cancer	2.99e-06	1.51e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—EGFR—bone cancer	2.99e-06	1.51e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IGF1R—bone cancer	2.98e-06	1.51e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—EGFR—bone cancer	2.98e-06	1.51e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—KIT—bone cancer	2.98e-06	1.51e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—JUN—bone cancer	2.98e-06	1.51e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MMP9—bone cancer	2.94e-06	1.49e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—MDM2—bone cancer	2.92e-06	1.48e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—TP53—bone cancer	2.91e-06	1.47e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—BRAF—bone cancer	2.91e-06	1.47e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MMP9—bone cancer	2.89e-06	1.47e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PTGS2—bone cancer	2.89e-06	1.46e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—EGFR—bone cancer	2.88e-06	1.46e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IGF1R—bone cancer	2.88e-06	1.46e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—JUN—bone cancer	2.87e-06	1.45e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—BRAF—bone cancer	2.86e-06	1.45e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—EGFR—bone cancer	2.86e-06	1.45e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—KIT—bone cancer	2.86e-06	1.45e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—TP53—bone cancer	2.85e-06	1.44e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—TP53—bone cancer	2.85e-06	1.44e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ENO2—bone cancer	2.85e-06	1.44e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—EGFR—bone cancer	2.84e-06	1.44e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—JUN—bone cancer	2.82e-06	1.43e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PTGS2—bone cancer	2.82e-06	1.43e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—MDM2—bone cancer	2.82e-06	1.43e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MDM2—bone cancer	2.8e-06	1.42e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—BRAF—bone cancer	2.8e-06	1.42e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MMP9—bone cancer	2.79e-06	1.41e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—TP53—bone cancer	2.78e-06	1.41e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—JUN—bone cancer	2.76e-06	1.4e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—JUN—bone cancer	2.76e-06	1.4e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TP53—bone cancer	2.76e-06	1.4e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—JUN—bone cancer	2.75e-06	1.39e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—EGFR—bone cancer	2.75e-06	1.39e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MDM2—bone cancer	2.73e-06	1.38e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—PTGS2—bone cancer	2.72e-06	1.37e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFBR2—bone cancer	2.71e-06	1.37e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PTGS2—bone cancer	2.7e-06	1.37e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—EGFR—bone cancer	2.69e-06	1.36e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—JUN—bone cancer	2.69e-06	1.36e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MDM2—bone cancer	2.69e-06	1.36e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MMP9—bone cancer	2.69e-06	1.36e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MMP9—bone cancer	2.69e-06	1.36e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—JUN—bone cancer	2.68e-06	1.36e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KIT—bone cancer	2.66e-06	1.35e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—JUN—bone cancer	2.66e-06	1.35e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—JUN—bone cancer	2.65e-06	1.34e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—DHFR—bone cancer	2.64e-06	1.34e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—EGFR—bone cancer	2.64e-06	1.34e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—JUN—bone cancer	2.64e-06	1.34e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—KIT—bone cancer	2.64e-06	1.33e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—MDM2—bone cancer	2.64e-06	1.33e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KIT—bone cancer	2.6e-06	1.32e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MMP9—bone cancer	2.59e-06	1.31e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MDM2—bone cancer	2.55e-06	1.29e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IGF1R—bone cancer	2.55e-06	1.29e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KIT—bone cancer	2.54e-06	1.29e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—MDM2—bone cancer	2.54e-06	1.29e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—EGFR—bone cancer	2.54e-06	1.28e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—EGFR—bone cancer	2.53e-06	1.28e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KIT—bone cancer	2.51e-06	1.27e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—BRAF—bone cancer	2.5e-06	1.27e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KIT—bone cancer	2.49e-06	1.26e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—BRAF—bone cancer	2.48e-06	1.25e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GNA11—bone cancer	2.47e-06	1.25e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—bone cancer	2.46e-06	1.25e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—BRAF—bone cancer	2.44e-06	1.24e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—MDM2—bone cancer	2.43e-06	1.23e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—EGFR—bone cancer	2.43e-06	1.23e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MDM2—bone cancer	2.4e-06	1.21e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—BRAF—bone cancer	2.39e-06	1.21e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—EGFR—bone cancer	2.37e-06	1.2e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—JUN—bone cancer	2.37e-06	1.2e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—BRAF—bone cancer	2.35e-06	1.19e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—PTGS2—bone cancer	2.35e-06	1.19e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—MDM2—bone cancer	2.35e-06	1.19e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—BRAF—bone cancer	2.34e-06	1.19e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—EGFR—bone cancer	2.34e-06	1.18e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—JUN—bone cancer	2.34e-06	1.18e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—bone cancer	2.31e-06	1.17e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MMP9—bone cancer	2.3e-06	1.17e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—JUN—bone cancer	2.29e-06	1.16e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MMP9—bone cancer	2.27e-06	1.15e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—EGFR—bone cancer	2.27e-06	1.15e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—PTGS2—bone cancer	2.26e-06	1.14e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—EGFR—bone cancer	2.25e-06	1.14e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—MDM2—bone cancer	2.25e-06	1.14e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CYP3A4—bone cancer	2.24e-06	1.13e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—EGFR—bone cancer	2.22e-06	1.12e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—JUN—bone cancer	2.22e-06	1.12e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—JUN—bone cancer	2.21e-06	1.12e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EGFR—bone cancer	2.17e-06	1.1e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EGFR—bone cancer	2.17e-06	1.1e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KIT—bone cancer	2.16e-06	1.1e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—EGFR—bone cancer	2.16e-06	1.1e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MMP9—bone cancer	2.16e-06	1.09e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—EGFR—bone cancer	2.12e-06	1.07e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—EGFR—bone cancer	2.11e-06	1.07e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MDM2—bone cancer	2.1e-06	1.06e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EGFR—bone cancer	2.09e-06	1.06e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—JUN—bone cancer	2.09e-06	1.06e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KIT—bone cancer	2.09e-06	1.06e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—EGFR—bone cancer	2.09e-06	1.06e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—MDM2—bone cancer	2.08e-06	1.05e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EGFR—bone cancer	2.07e-06	1.05e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—EGFR—bone cancer	2.05e-06	1.04e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MDM2—bone cancer	2.05e-06	1.04e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—BRAF—bone cancer	2.03e-06	1.03e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MMP9—bone cancer	2.03e-06	1.03e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MDM2—bone cancer	2e-06	1.01e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—PTGS2—bone cancer	2e-06	1.01e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EGFR—bone cancer	2e-06	1.01e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—bone cancer	1.99e-06	1.01e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MDM2—bone cancer	1.97e-06	9.99e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—bone cancer	1.96e-06	9.94e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MDM2—bone cancer	1.96e-06	9.93e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—BRAF—bone cancer	1.96e-06	9.92e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—JUN—bone cancer	1.96e-06	9.89e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—EGFR—bone cancer	1.93e-06	9.74e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EGFR—bone cancer	1.92e-06	9.69e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GSTP1—bone cancer	1.91e-06	9.69e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—bone cancer	1.89e-06	9.57e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EGFR—bone cancer	1.86e-06	9.43e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KIT—bone cancer	1.85e-06	9.35e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EGFR—bone cancer	1.84e-06	9.3e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—JUN—bone cancer	1.82e-06	9.23e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—bone cancer	1.82e-06	9.22e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—bone cancer	1.82e-06	9.22e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—JUN—bone cancer	1.78e-06	9e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP9—bone cancer	1.77e-06	8.98e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—bone cancer	1.76e-06	8.89e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ENO2—bone cancer	1.75e-06	8.88e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—bone cancer	1.74e-06	8.82e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—JUN—bone cancer	1.74e-06	8.82e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—bone cancer	1.74e-06	8.79e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—BRAF—bone cancer	1.74e-06	8.78e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—bone cancer	1.73e-06	8.76e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—JUN—bone cancer	1.72e-06	8.68e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—JUN—bone cancer	1.71e-06	8.63e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MDM2—bone cancer	1.7e-06	8.63e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—bone cancer	1.69e-06	8.58e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—bone cancer	1.67e-06	8.44e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—bone cancer	1.66e-06	8.4e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MDM2—bone cancer	1.64e-06	8.31e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—bone cancer	1.64e-06	8.3e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—DHFR—bone cancer	1.63e-06	8.24e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—bone cancer	1.6e-06	8.11e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—bone cancer	1.56e-06	7.91e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—bone cancer	1.54e-06	7.81e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—bone cancer	1.54e-06	7.78e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GNA11—bone cancer	1.52e-06	7.7e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—JUN—bone cancer	1.48e-06	7.5e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—bone cancer	1.46e-06	7.4e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MDM2—bone cancer	1.45e-06	7.36e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—bone cancer	1.44e-06	7.3e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—bone cancer	1.43e-06	7.25e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—JUN—bone cancer	1.43e-06	7.23e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—bone cancer	1.42e-06	7.18e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—bone cancer	1.4e-06	7.08e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—bone cancer	1.39e-06	7.03e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—bone cancer	1.38e-06	6.97e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—bone cancer	1.37e-06	6.93e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—bone cancer	1.35e-06	6.82e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—bone cancer	1.34e-06	6.79e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—JUN—bone cancer	1.26e-06	6.4e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—bone cancer	1.23e-06	6.22e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—bone cancer	1.2e-06	6.09e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTP1—bone cancer	1.18e-06	5.97e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—bone cancer	1.17e-06	5.94e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—bone cancer	1.15e-06	5.82e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—bone cancer	1.13e-06	5.73e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—bone cancer	1.13e-06	5.7e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—bone cancer	1.12e-06	5.68e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—bone cancer	9.94e-07	5.03e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—bone cancer	9.92e-07	5.02e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—bone cancer	9.78e-07	4.95e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—bone cancer	9.43e-07	4.77e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—bone cancer	8.34e-07	4.22e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—bone cancer	6.11e-07	3.09e-06	CbGpPWpGaD
